Filhol O, Baudier J, Delphin C, Loue-Mackenbach P, Chambaz E M, Cochet C
Institut National de la Santé et de la Recherche Médicale Unité 244, Biochimie de Régulations Cellulaires et Endocrines, Grenoble, France.
J Biol Chem. 1992 Oct 15;267(29):20577-83.
Selective immunoisolation of P53 from Sf9 cells coexpressing wild-type P53 and casein kinase II yielded a preparation containing casein kinase II, thus suggesting that the two proteins may associate in a molecular complex in the intact cell. Such a complex could indeed be demonstrated in vitro between purified recombinant P53 and oligomeric casein kinase II and was shown to dissociate when P53 became phosphorylated by the kinase. This suggested that the P53 C-terminal domain, which contains the casein kinase II phosphorylation site was involved in the protein-protein interaction; this was confirmed by the fact that an anti-P53 monoclonal antibody directed to that domain inhibited the P53-casein kinase II association. Studies with isolated recombinant casein kinase II subunits disclosed that although the alpha (catalytic) subunit could phosphorylate P53, the formation of a stable P53-casein kinase II association required the presence of the beta subunit of the kinase. This was confirmed by immunoisolation of a P53-beta subunit complex from cells expressing both polypeptides. Although the biological significance of a reversible P53-casein kinase II molecular complex in the control of cell proliferation processes remains to be defined, these observations suggest the possibility of a novel mechanism regulating P53 and casein kinase II activities in the intact cell.
从共表达野生型P53和酪蛋白激酶II的Sf9细胞中选择性免疫分离P53,得到了一种含有酪蛋白激酶II的制剂,这表明这两种蛋白质可能在完整细胞中以分子复合物的形式结合。在纯化的重组P53和寡聚酪蛋白激酶II之间确实能在体外证明这样一种复合物,并且当P53被该激酶磷酸化时,复合物会解离。这表明包含酪蛋白激酶II磷酸化位点的P53 C末端结构域参与了蛋白质 - 蛋白质相互作用;这一点得到了针对该结构域的抗P53单克隆抗体抑制P53 - 酪蛋白激酶II结合这一事实的证实。对分离的重组酪蛋白激酶II亚基的研究表明,虽然α(催化)亚基可以磷酸化P53,但稳定的P53 - 酪蛋白激酶II结合的形成需要该激酶的β亚基的存在。这通过从表达这两种多肽的细胞中免疫分离P53 - β亚基复合物得到了证实。尽管P53 - 酪蛋白激酶II可逆分子复合物在细胞增殖过程控制中的生物学意义仍有待确定,但这些观察结果提示了一种在完整细胞中调节P53和酪蛋白激酶II活性的新机制的可能性。